These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

576 related articles for article (PubMed ID: 30222111)

  • 21. Sex differences in the efficacy of omalizumab in the treatment of chronic spontaneous urticaria.
    Sirufo MM; Bassino EM; De Pietro F; Ginaldi L; De Martinis M
    Int J Immunopathol Pharmacol; 2021; 35():20587384211065870. PubMed ID: 35170369
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Case Report: Omalizumab for Chronic Spontaneous Urticaria in Pregnancy.
    Liao SL; Yu M; Zhao ZT; Maurer M
    Front Immunol; 2021; 12():652973. PubMed ID: 33796115
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of clinical factors as possible predictors of response to omalizumab and relapse after treatment discontinuation in chronic spontaneous urticaria.
    Foti C; Romita P; Ambrogio F; Fanelli M; Panebianco R; Vena GA; Cassano N; Ragusa M; Giuffrida R; Papaianni V; Borgia F; Cannavò SP; Guarneri F
    Dermatol Ther; 2022 Feb; 35(2):e15248. PubMed ID: 34877757
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of Pharmacologic Treatments for H1 Antihistamine-Refractory Chronic Spontaneous Urticaria: A Systematic Review and Network Meta-analysis.
    Nochaiwong S; Chuamanochan M; Ruengorn C; Awiphan R; Tovanabutra N; Chiewchanvit S
    JAMA Dermatol; 2021 Nov; 157(11):1316-1327. PubMed ID: 34431983
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Omalizumab in Chronic Spontaneous Urticaria: A Brazilian Real-Life Experience.
    Ensina LF; Valle SO; Juliani AP; Galeane M; Vieira dos Santos R; Arruda LK; Melo JM; de Souza PK; Serpa FS; de Andrade DM; França AT; Campos RA; Camelo-Nunes I; Solé D
    Int Arch Allergy Immunol; 2016; 169(2):121-4. PubMed ID: 27055122
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A retrospective analysis omalizumab treatment patterns in patients with chronic spontaneous urticaria: a real-world study in Belgium.
    Lapeere H; Baeck M; Stockman A; Sabato V; Grosber M; Moutschen M; Lambert J; Vandebuerie L; de Montjoye L; Rabijns H; Allewaert K; Schrijvers R
    J Eur Acad Dermatol Venereol; 2020 Jan; 34(1):127-134. PubMed ID: 31099916
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of omalizumab treatment for pediatric chronic spontaneous urticaria: A multi-center retrospective case series.
    Ari A; Levy Y; Segal N; Maoz-Segal R; Benor S; Broides A; Horev A; Epstein-Rigbi N; Agmon-Levin N; Marcus N
    Pediatr Dermatol; 2020 Nov; 37(6):1051-1054. PubMed ID: 32951239
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Determinants of omalizumab drug survival in a long-term daily practice cohort of patients with chronic urticaria.
    Spekhorst LS; van den Reek JMPA; Knulst AC; Röckmann H
    Allergy; 2019 Jun; 74(6):1185-1187. PubMed ID: 30593687
    [No Abstract]   [Full Text] [Related]  

  • 29. Efficacy and safety of omalizumab in Chinese patients with anti-histamine refractory chronic spontaneous urticaria.
    Yuan W; Hu S; Li M; Yang L; Liu L; Zheng M; Guo Z; Song Z; Zhang C; Diao Q; Xu J; Richard A; Patwardhan M; Lyu T; Uddin A; Fogel R; Ligueros-Saylan M; Zheng J
    Dermatol Ther; 2022 Apr; 35(4):e15303. PubMed ID: 34984792
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical management of urticaria using omalizumab: the first licensed biological therapy available for chronic spontaneous urticaria.
    Giménez-Arnau AM; Toubi E; Marsland AM; Maurer M
    J Eur Acad Dermatol Venereol; 2016 Jul; 30 Suppl 5():25-32. PubMed ID: 27286500
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Omalizumab for the treatment of chronic spontaneous urticaria: A meta-analysis of randomized clinical trials.
    Zhao ZT; Ji CM; Yu WJ; Meng L; Hawro T; Wei JF; Maurer M
    J Allergy Clin Immunol; 2016 Jun; 137(6):1742-1750.e4. PubMed ID: 27040372
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Omalizumab in patients with chronic spontaneous urticaria nonresponsive to H1-antihistamine treatment: results of the phase IV open-label SUNRISE study.
    Bérard F; Ferrier Le Bouedec MC; Bouillet L; Reguiai Z; Barbaud A; Cambazard F; Milpied B; Pelvet B; Kasujee I; Gharbi H; Lacour JP
    Br J Dermatol; 2019 Jan; 180(1):56-66. PubMed ID: 29927483
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term management of chronic spontaneous urticaria with omalizumab.
    Pinto Gouveia M; Gameiro A; Pinho A; Gonçalo M
    Clin Exp Dermatol; 2017 Oct; 42(7):735-742. PubMed ID: 28649751
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Omalizumab in the Treatment of Chronic Urticaria: The Effect of Drug Co-Administration and Co-Morbidities.
    Tagka A; Lambrou GI; Nicolaidou E; Nakou E; Makris M; Stratigos A; Katsarou A
    Antiinflamm Antiallergy Agents Med Chem; 2021; 20(1):39-50. PubMed ID: 32013838
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antihistamine-resistant chronic spontaneous urticaria: 1-year data from the AWARE study.
    Maurer M; Raap U; Staubach P; Richter-Huhn G; Bauer A; Oppel EM; Hillen U; Baeumer D; Reinhardt M; Chapman-Rothe N
    Clin Exp Allergy; 2019 May; 49(5):655-662. PubMed ID: 30415478
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness of Hydroxychloroquine and Omalizumab in Chronic Spontaneous Urticaria: A Real-World Study.
    Khan N; Epstein TG; DuBuske I; Strobel M; Bernstein DI
    J Allergy Clin Immunol Pract; 2022 Dec; 10(12):3300-3305. PubMed ID: 36115542
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expert opinion: defining response to omalizumab in patients with chronic spontaneous urticaria.
    Ferrer M; Boccon-Gibod I; Gonçalo M; İnalöz HS; Knulst A; Lapeere H; Parthasaradhi A; Stingl G; Tagka A; Valenzuela F; Yeung J; Thomsen SF
    Eur J Dermatol; 2017 Oct; 27(5):455-463. PubMed ID: 29084635
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The impact of omalizumab on quality of life and its predictors in patients with chronic spontaneous urticaria: Real-life data.
    Salman A; Demir G; Bekiroglu N
    Dermatol Ther; 2019 Jul; 32(4):e12975. PubMed ID: 31145524
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A patient-oriented approach to long-term use of omalizumab in chronic spontaneous urticaria.
    Ornek S; Kocaturk E
    Cutan Ocul Toxicol; 2021 Dec; 40(4):305-311. PubMed ID: 34212792
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and Safety of Omalizumab for Chronic Spontaneous Urticaria: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Jia HX; He YL
    Am J Ther; 2020; 27(5):e455-e467. PubMed ID: 32427616
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.